Hyper-CVAD + ponatinib vs. hyper-CVAD + dasatinib as frontline therapy for Ph-positive ALL: a propensity score analysis

Por Sasaki, Koji, Jabbour, Elias, Ravandi, Farhad, Short, Nicholas J., Thomas, Deborah, Garcia-Manero, Guillermo, Daver, Naval, Kadia, Tapan, Konopleva, Marina, Jain, Nitin, Issa, Ghayas C., Jeanis, Vicki, Moore, Gal, Garris, Rebecca, Pemmaraju, Naveen, Cortes, Jorge E., O'Brien, Susan, Kantarjian, Hagop
Publicado no Cancer (2016)